A Double Blind, Double Dummy, Randomised, Multicentre, Two Arm Parallel Group Study to Assess the Efficacy and Safety of FLUTIFORM® pMDI (2 Puffs Bid) vs Seretide® pMDI (2 Puffs Bid) in Subjects Aged ≥12 Years With Moderate to Severe Persistent, Reversible Asthma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Formoterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Mundipharma (China) Pharmaceutical
- 26 Apr 2019 Planned End Date changed from 10 Dec 2017 to 30 Mar 2020.
- 26 Apr 2019 Planned primary completion date changed from 30 Nov 2017 to 30 Dec 2019.
- 06 Sep 2017 Status changed from planning to recruiting, according to a Vectura media release